1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E1FD1918AC57F37800258D1E003E9DE6
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/cns-medical-affairs-impact-equation-linking-activities-strategic-outcomes-real-world
18
19
20216.73.216.147
21
22
23globalbenchmarking.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Medical Affairs » Medical Affairs Excellence

CNS Medical Affairs Impact Equation: Linking Activities with Strategic Outcomes to Drive Real-World Impact

ID: POP-413


Features:

19 Info Graphics

20 Data Graphics

350+ Metrics

16 Narratives


Pages: 48


Published: 2025


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Medical Affairs is transforming from a tactical function to a strategic driver of clinical and organizational success in CNS. This report presents a proven framework to measure Medical Affairs impact through clear indicators, robust linkage assessments, and real-world evidence (RWE) integration. It connects leading Medical activities— including MSL insights, targeted scientific exchange, and evidence generation — to strategic outcomes,such as guideline updates, treatment adoption, and optimized care pathways.

By translating daily Medical Affairs activities into
measurable business and patient outcomes, organizations can tell a compelling, data-driven story that resonates with the C-suite, payers, and clinical leaders.

As CNS therapies and care models grow increasingly complex, top-performing Medical Affairs teams are closing the activity-to-outcome gap through cross-functional alignment, advanced analytics, and targeted measurement strategies.

Explore how your CNS Medical Affairs organization can quantify its strategic value—and turn insight into real-world impact.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Health Care; Medical Device


Companies Profiled:
AbbVie; Alnylam Pharmaceuticals; Amgen; Azurity Pharmaceuticals; Boehringer Ingelheim; Eurofarma; Jazz Pharmaceuticals; Johnson & Johnson; Otsuka; Scholar Rock; Supernus; Takeda

Study Snapshot

Best Practices, LLC engaged 16 Medical Affairs executives from 12 CNS-focused biopharma companies. In-depth interviews further provide a closer look at how CNS Medical Affairs teams are mapping activity-to-outcome linkages and developing impact narratives that resonate with leadership.

Key topics covered in this report include:

  • CNS Medical Affairs Leading and Lagging Indicators
  • Strategic Impact Measurement Frameworks
  • Real-World Data Sources and Linkability
  • CNS Medical Insights and Launch Success
  • Performance Measurement and KPIs

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Linking Activities to Outcomes Is the New Standard: 75% of CNS Medical groups now connect at least some tactical activities to measurable external outcomes—setting a new standard for accountability and influence.
  • Leading Field Indicators: Top field activity metrics deemed either “somewhat” or “highly important” for showing medical value by a majority of CNS benchmark respondents: 1) Insights from MSL interactions, 2) scientific concepts discussed, 3) total interactions, 4) % territory engaged, and 5) F2F %. Their prominence suggests Medical Affairs should sharpen how these metrics are defined and used to reflect true medical value.
  • Lagging Indicators Vary by Product Stage: 78% of organizations use different lagging indicators for launches versus mature therapies, showing a lifecycle-aware approach. This reinforces the importance of tailoring measurement strategies to product maturity to ensure relevance and strategic alignment.
Table of Contents

Sr. No.
Topic
Slide No.
I. Executive SummaryPg. 5
II. Leading Indicators Which Demonstrate ValuePg. 15
III. Linking Leading & Lagging IndicatorsPg. 21
IV. Lagging Indicators of Medical ImpactPg. 28
V. Assessing Metrics, Outcomes & Data Sources for High ImpactPg. 39
VI. Respondent DemographicsPg. 46
VII. About Best Practices, LLCPg. 48

    List of Charts & Exhibits

    I. Executive Summary

    • One-page executive summary
    • Participating CNS-focused benchmark companies
    • Executive takeaways from the study
    • Medical impact cycle: Connecting activities to strategic outcomes
    • Key quantitative study findings
    • Insights vs. impact pathway

    II. Leading Indicators Which Demonstrate Value

    • Top-rated activity metrics across CNS Medical Affairs
    • Case study: Measuring MSL strategic impact across three workstreams
    • Top CNS-focused field activity metrics
    • Top CNS-focused non-field activity metrics
    • Cycle of impact: Real-world examples showing the impact of disease awareness and knowledge retention

    III. Linking Leading & Lagging Indicators

    • Benchmark activities to outcomes linkage rates across CNS organizations
    • Most linkable CNS medical activities to key external outcomes
    • Most linkable CNS-focused field activities to critical external outcomes
    • Cycle of impact: Real-world examples showing the impact of medical insights
    • Most linkable CNS-focused non-field activities to critical external outcomes
    • Cycle of impact: Real-world examples showing the impact of Congress presentations and post-Congress tracking

    IV. Lagging Indicators of Medical Impact

    • Case study: Driving strategic outcomes through AI-identified care gaps and targeted MSL engagement
    • Prioritizing strategic outcomes and evaluating linkability to CNS-focused medical activities
    • Measuring the gap between outcome importance and linkability
    • Linkability trends across lagging indicators
    • Linking real-world data outcomes to CNS-focused medical activities
    • Connecting provider-level outcomes to tactical CNS medical engagement
    • Measuring CNS Medical’s influence on launch strategy, guidelines, and access
    • Cycle of impact: Real-world examples showing the impact of patient support
    • Cycle of impact: Real-world examples showing the impact of disease awareness and knowledge retention through field and digital engagement
    • Key challenges in linking CNS medical tactics to strategic outcomes

    V. Assessing Metrics, Outcomes & Data Sources for High Impact

    • Differentiating activity metrics between new and mature CNS products
    • Tailoring strategic outcome measurement to product lifecycle stage
    • Revisiting metrics over time to align CNS-focused activities with strategic goals
    • Navigating competing strategic objectives across medical levels
    • Critical data sources to trace CNS medical impact
    • Tracking data granularity to strengthen activity-to-outcome linkage

    VI. Respondent Demographics

    • Geographic coverage of benchmarked CNS Medical Affairs roles